MedWaves reports on its ongoing studies using the AveCure microwave coagulation-ablation system

Sep 19 2009

MedWaves, Inc. announces ongoing investigational studies to determine the effectiveness of its microwave ablation system for treating soft tissue lesions, such as tumors, in liver and lung. The studies using MedWaves' AveCure(TM) microwave coagulation-ablation system, which includes a generator and probe/antenna (FDA 510(k) cleared and CE Mark certified), are showing promising results.

The AveCure(TM) system, which includes a microwave generator and sterile single-patient-use probes, enables the surgeons and interventional radiologists to safely treat soft tissue problems, such as tumors in the liver and lung, using thermal coagulation-ablation. AveCure(TM) system uses temperature and power feedback from the antenna and nearby tissue to intelligently control microwave power to the ablation zone. The changes in temperature and power absorption are indicative of thermal tissue destruction brought on by microwave energy absorbed in the ablation zone. By utilizing and displaying dynamic changes in temperature and power, MedWaves' AveCure(TM) system safely and efficiently ablates small or large zones using far less power than other ablation systems in the market. The same feedbacks are available for the user to manage the ablation process with confidence. Therefore, MedWaves' is inherently safer, does not require irrigation cooling, and less likely to cause collateral damage as with other systems currently in the market.